Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Antibacterial drugs

New antibiotics on the horizon?

Credit: PhotoDisc/Getty Images\Stephen F Hayes

Staphylococcus aureus is responsible for a variety of diseases ranging from skin and soft-tissue infections to pneumonia and sepsis. The increasing prevalence of multidrug-resistant bacterial strains and the lack of new classes of antibiotics have together made the effective treatment of such infections challenging. Now, two recent papers report novel strategies for combating this prevalent bacterial pathogen.

S. aureus secretes several factors that are toxic to human immune cells, including several pore-forming leukotoxins. However, the specific range of immune cells that are targeted by such leukotoxins and the host factors responsible for their selectivity remain unclear. Torres and colleagues therefore set out to identify potential leukotoxin receptors, with the aim of identifying novel therapeutic targets.

The authors first purified recombinant leukotoxins and assessed their ability to kill a set of human cell lines. They discovered that the leukotoxin LukED only displayed cytotoxicity to human T cell lines ectopically expressing CC chemokine receptor 5 (CCR5; a co-receptor required for HIV infection). Further in vitro experiments showed that LukED interacted directly with CCR5 and specifically targeted human T cells, macrophages and dendritic cells.

Next, they assessed whether LukED-mediated cell killing could be prevented by blocking the CCR5–toxin interaction. They found that CCR5 antagonists, including the clinically approved HIV therapeutic maraviroc, blocked LukED-mediated pore formation and killing of CCR5+ T cells. Furthermore, S. aureus-mediated CCR5+ T cell cytotoxicity was dependent on LukED and completely blocked by maraviroc.

Finally, they examined the contribution of CCR5 to S. aureus pathogenesis in vivo. S. aureus-elicited lymphocytes and macrophages from wild-type mice were highly susceptible to purified LukED, whereas those from Ccr5−/− mice were markedly resistant. Moreover, Ccr5−/− mice were largely resistant to lethal S. aureus infections, further supporting the potential of CCR5 blockade as a novel antibacterial strategy.

Meanwhile, Oldfield and colleagues set out to inhibit the early steps of S. aureus cell wall peptidoglycan biosynthesis. Specifically, they targeted an enzyme in the isoprenoid biosynthesis pathway — undecaprenyl pyrophosphate synthase (UppS), which catalyses the formation of undecaprenyl pyrophosphate. UppS inhibitors are predicted to synergize with existing cell wall biosynthesis inhibitors (such as vancomycin and methicillin), which act in the later stages of peptidoglycan formation, potentially reducing toxicity or restoring drug sensitivity.

Using in silico high-throughput screening and hit development, the authors produced a small series of benzoic, phosphonic and diketo acids, as well as a bisamidine and a bisamine, that were active against UppS. Analysis of the X-ray crystal structures of the inhibitors bound to UppS revealed them to bind to one or more of four previously identified UppS inhibitor-binding sites, with the most potent leads binding to a site located outside the catalytic centre. The most potent inhibitor — the biphenyl bisamidine — potently synergized with methicillin to inhibit S. aureus growth in vitro. Importantly, the biphenyl bisamidine was also active in vivo, protecting mice from a lethal S. aureus strain when given post-infection.

In summary, these studies identify novel therapeutic targets and compounds that may lead to the development of new approaches for treating and preventing resistant S. aureus infections.

ORIGINAL RESEARCH PAPERS

  1. Alonzo, F. et al. CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. Nature 493, 51–55 (2013)

    Article  PubMed  Google Scholar 

  2. Zhu, W. et al. Antibacterial drug leads targeting isoprenoid biosynthesis. Proc. Natl Acad. Sci. USA 110, 123–128 (2013)

    CAS  Article  PubMed  Google Scholar 

Download references

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Crunkhorn, S. New antibiotics on the horizon?. Nat Rev Drug Discov 12, 99 (2013). https://doi.org/10.1038/nrd3940

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3940

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing